Alexion Pharmaceuticals, Inc. (ALXN): Price and Financial Metrics


Alexion Pharmaceuticals, Inc. (ALXN)

Today's Latest Price: $120.51 USD

0.55 (-0.45%)

Updated Dec 4 4:00pm

Add ALXN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

ALXN Stock Summary

  • ALXN has a market capitalization of $26,863,276,778 -- more than approximately 91.94% of US stocks.
  • Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 15.11% of US stocks have a lower such ratio.
  • As for revenue growth, note that ALXN's revenue has grown 23.79% over the past 12 months; that beats the revenue growth of 81.62% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Alexion Pharmaceuticals Inc are SLB, VIPS, CHA, PCAR, and ZBRA.
  • Visit ALXN's SEC page to see the company's official filings. To visit the company's web site, go to www.alexion.com.

ALXN Stock Price Chart Interactive Chart >

Price chart for ALXN

ALXN Price/Volume Stats

Current price $120.51 52-week high $128.57
Prev. close $121.06 52-week low $72.67
Day low $119.40 Volume 1,012,300
Day high $121.45 Avg. volume 2,135,417
50-day MA $121.19 Dividend yield N/A
200-day MA $107.83 Market Cap 26.37B

Alexion Pharmaceuticals, Inc. (ALXN) Company Bio


Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.

ALXN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$120.51$393.4 220%

We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 71th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 222% on a DCF basis. The most interesting components of our discounted cash flow analysis for Alexion Pharmaceuticals Inc ended up being:

  • As a business, ALXN is generating more cash flow than 87.01% of positive cash flow stocks in the Healthcare.
  • ALXN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 36.99% of tickers in our DCF set.
  • Alexion Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%214%
1%217%
2%220%
3%224%
4%227%
5%230%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ALXN, try ABBV, FTLF, ARA, HUM, and SGRY.


ALXN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALXN Latest Social Stream


Loading social stream, please wait...

View Full ALXN Social Stream

Latest ALXN News From Around the Web

Below are the latest news stories about Alexion Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALXN as an investment opportunity.

Alexion' Ultomiris ok'd in Japan

Japan’s Ministry of Health, Labour and Welfare has approved Alexion Pharmaceuticals' (ALXN) Ultomiris (ravulizumab) for atypical hemolytic uremic syndrome (aHUS), for use in adults and children.Ultomiris is a long-acting C5 inhibitor for aHUS and is administered every other month for adults and children (20 kg or more) and monthly for children (<20 kg).Atypical HUS is an...

Seeking Alpha | September 25, 2020

Alexion' Ultomiris ok'd in Japan (NASDAQ:ALXN)

Japan’s Ministry of Health, Labour and Welfare has approved Alexion Pharmaceuticals' (NASDAQ:ALXN) Ultomiris (ravulizumab) for atypical hemolytic uremic sy

Seeking Alpha | September 25, 2020

European advisory group backs new formulation of Alexion's Ultomiris

Alexion Pharmaceuticals (ALXN) announces that the Committee for Medicinal Products for Human Use ((CHMP)) has adopted a positive opinion, recommending marketing authorization in the European Union for a new 100 mg/mL intravenous ((IV)) advanced formulation of ULTOMIRIS (ravulizumab).ULTOMIRIS 100 mg/mL would constitute an advancement in the treatment experience by reducing...

Seeking Alpha | September 21, 2020

European advisory group backs new formulation of Alexion's Ultomiris (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) announces that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending

Seeking Alpha | September 21, 2020

A Look Into Alexion Pharmaceuticals's Price Over Earnings

In the current session, Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is trading at $108.21, after a 2.71% spike. Over the past …

Benzinga | September 14, 2020

Read More 'ALXN' Stories Here

ALXN Price Returns

1-mo -3.93%
3-mo 6.67%
6-mo 0.64%
1-year 5.81%
3-year 10.14%
5-year -32.73%
YTD 11.43%
2019 11.08%
2018 -18.59%
2017 -2.26%
2016 -35.86%
2015 3.09%

Continue Researching ALXN

Want to see what other sources are saying about Alexion Pharmaceuticals Inc's financials and stock price? Try the links below:

Alexion Pharmaceuticals Inc (ALXN) Stock Price | Nasdaq
Alexion Pharmaceuticals Inc (ALXN) Stock Quote, History and News - Yahoo Finance
Alexion Pharmaceuticals Inc (ALXN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.3237 seconds.